Want to see JP:4886 full AI Analyst Report?
4886 Stock Chart & Stats
¥2038.00
-¥23.00(-1.13%)
At close: 4:00 PM EST
¥2038.00
-¥23.00(-1.13%)
Day’s Range― - ―
52-Week Range¥1,917.00 - ¥3,045.00
Previous CloseN/A
Volume48.10K
Average Volume (3M)92.14K
Market Cap
¥54.53B
Enterprise Value¥73.89K
Total Cash (Recent Filing)¥7.11B
Total Debt (Recent Filing)¥11.84B
Price to Earnings (P/E)12.3
Beta0.46
Next Earnings
Nov 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.93%
Share Statistics
EPS (TTM)165.99
Shares Outstanding28,763,199
10 Day Avg. Volume55,180
30 Day Avg. Volume92,136
Financial Highlights & Ratios
PEG Ratio1.99
Price to Book (P/B)0.96
Price to Sales (P/S)0.94
P/FCF Ratio17.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)197.8
Revenue Forecast (FY)¥71.06B
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthSustained revenue expansion indicates durable demand for the group’s prescription pharmaceutical portfolio and provides a growing base to support manufacturing scale, commercial investment, and recurring earnings over the medium term.
Strengthened Balance SheetSharp debt reduction alongside substantial equity growth lowers financial risk and improves resilience. The stronger capital structure should provide greater flexibility to fund pharmaceutical development, operations, and strategic initiatives.
Recurring ProfitabilityHealthy gross profit and recurring profitability suggest the established prescription portfolio can generate operating returns beyond individual product cycles, supporting continued investment while limiting dependence on external financing.
Bears Say
Volatile Cash GenerationUneven operating and free cash flow reduces earnings quality and makes internally funded investment less predictable. Working-capital movements or investment timing could continue to create variability despite the latest recovery.
Uneven Earnings PerformanceYear-to-year earnings variability indicates that revenue growth has not translated consistently into bottom-line expansion. Continued fluctuations could constrain planning and reduce confidence in the pace of profit compounding.
Variable Profit EfficiencyFluctuating returns on equity suggest the enlarged capital base has not produced consistently improving profit efficiency. If this persists, shareholder returns may remain dependent on balance-sheet strength rather than operating productivity.
ASKA Pharmaceutical Holdings Co., Ltd. News
4886 FAQ
What was ASKA Pharmaceutical Holdings Co., Ltd.’s price range in the past 12 months?
ASKA Pharmaceutical Holdings Co., Ltd. lowest stock price was ¥1917.00 and its highest was ¥3045.00 in the past 12 months.
What is ASKA Pharmaceutical Holdings Co., Ltd.’s market cap?
ASKA Pharmaceutical Holdings Co., Ltd.’s market cap is ¥54.53B.
When is ASKA Pharmaceutical Holdings Co., Ltd.’s upcoming earnings report date?
ASKA Pharmaceutical Holdings Co., Ltd.’s upcoming earnings report date is Nov 09, 2026 which is in 64 days.
How were ASKA Pharmaceutical Holdings Co., Ltd.’s earnings last quarter?
ASKA Pharmaceutical Holdings Co., Ltd. released its earnings results on Aug 04, 2026. The company reported ¥18.78 earnings per share for the quarter.
Is ASKA Pharmaceutical Holdings Co., Ltd. overvalued?
According to Wall Street analysts ASKA Pharmaceutical Holdings Co., Ltd.’s price is currently Overvalued.
Does ASKA Pharmaceutical Holdings Co., Ltd. pay dividends?
ASKA Pharmaceutical Holdings Co., Ltd. pays a Semiannually dividend of ¥32 which represents an annual dividend yield of 2.93%. See more information on ASKA Pharmaceutical Holdings Co., Ltd. dividends here
What is ASKA Pharmaceutical Holdings Co., Ltd.’s EPS estimate?
ASKA Pharmaceutical Holdings Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ASKA Pharmaceutical Holdings Co., Ltd. have?
ASKA Pharmaceutical Holdings Co., Ltd. has 28,763,199 shares outstanding.
What happened to ASKA Pharmaceutical Holdings Co., Ltd.’s price movement after its last earnings report?
ASKA Pharmaceutical Holdings Co., Ltd. reported an EPS of ¥18.78 in its last earnings report. Following the earnings report the stock price went up 0.375%.
Which hedge fund is a major shareholder of ASKA Pharmaceutical Holdings Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4886
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ASKA Pharmaceutical Holdings Co., Ltd.
ASKA Pharmaceutical Holdings Co.,Ltd. is a Japanese enterprise that operates through its subsidiaries in three primary areas: pharmaceuticals, animal healthcare, and hormone testing services. The company's pharmaceutical division is dedicated to the research, development, production, and commercialization of medications, with a specific focus on endocrinology, obstetrics and gynecology, and urology. Within its animal health segment, ASKA manufactures, sells, imports, and exports a broad spectrum of veterinary products, such as medicines, medical equipment, animal feed and supplements, laboratory reagents, agricultural chemicals, industrial chemicals, hygiene products, and food items along with their raw materials. Beyond these activities, the company also performs clinical and biological testing and offers medical devices. Founded in 1920, ASKA Pharmaceutical Holdings Co.,Ltd. is headquartered in Tokyo, Japan.
Technical Analysis
Kaken Pharmaceutical Co
―
Fuji Pharma Co., Ltd.
―
Mochida Pharmaceutical Co., Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
Daito Pharmaceutical Co., Ltd.
―